Replies to post #1170 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

If Harvoni will remain GILD’s preferred treatment for GT1 patients, what impact this 12-week regimen of Sovaldi/Velpatasvir will have on V Pak?

Little, if any effect, IMO; in the US, V-Pak is approved only for GT1, and Technivive (a 2-DAA subset of V-Pak) is approved only for GT4.